Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression.
Adult
Depression, Postpartum
/ diagnosis
Drug Combinations
Female
Humans
Mass Screening
Patient Health Questionnaire
/ standards
Patient Reported Outcome Measures
Pregnanolone
/ administration & dosage
Psychiatric Status Rating Scales
/ standards
Sensitivity and Specificity
Severity of Illness Index
Surveys and Questionnaires
/ standards
beta-Cyclodextrins
/ administration & dosage
Edinburgh Postnatal Depression Scale
Hamilton Depression Rating Scale
Patient Health Questionnaire-9
Postpartum depression
Postpartum depression screening
Journal
Archives of women's mental health
ISSN: 1435-1102
Titre abrégé: Arch Womens Ment Health
Pays: Austria
ID NLM: 9815663
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
10
02
2020
accepted:
26
05
2020
pubmed:
16
7
2020
medline:
18
11
2020
entrez:
16
7
2020
Statut:
ppublish
Résumé
The objective of this study is to explore the associations between the patient-reported Edinburgh Postnatal Depression Scale (EPDS) and Patient Health Questionnaire (PHQ)-9 and clinician-reported 17-item Hamilton Depression Rating Scale (HAMD-17) in order to facilitate clinical decision-making. An integrated efficacy dataset of three randomized placebo-controlled trials (NCT02614547, NCT02942004, and NCT02942017) evaluating brexanolone injection, a neuroactive steroid chemically identical to allopregnanolone, in women with postpartum depression was used for this post hoc analysis. Data were pooled across treatment arms. Associations were assessed at day 30 (end-of-trial follow-up). Pearson correlation assessed the relationship between EPDS and PHQ-9 item and total scores and HAMD-17 total score. Cohen's kappa assessed agreement of EPDS remission (score < 10) and PHQ-9 remission (score < 5) with HAMD-17 remission (score ≤ 7). Ordinary least squares (OLS) regression models were used to develop equations estimating HAMD-17 total scores from EPDS and PHQ-9 scores, respectively. The total scores showed large correlations (HAMD-17/EPDS: r = 0.71, p < 0.001; HAMD-17/PHQ-9: r = 0.75, p < 0.001). Individual EPDS and PHQ-9 items significantly correlated (r= 0.35 to 0.67, all p < 0.001) with HAMD-17 total score. EPDS had 79% sensitivity and 67% specificity to detect HAMD-17 remission; corresponding estimates for PHQ-9 were 76% and 78%. OLS models yielded the following equations: HAMD-17 total = 2.66 + (EPDS total × 0.87) and HAMD-17 total = 3.99 + (PHQ-9 total × 0.97). There were large and statistically significant associations between patient-reported outcomes (EPDS, PHQ-9) and clinician-reported outcomes (HAMD-17) as clinical improvements were associated with patient-reported symptom improvement. These results provide tools to help translate clinical trial data to clinical practice, thus aiding shared decision-making for this critical population.
Identifiants
pubmed: 32666402
doi: 10.1007/s00737-020-01042-y
pii: 10.1007/s00737-020-01042-y
pmc: PMC7497318
doi:
Substances chimiques
Drug Combinations
0
beta-Cyclodextrins
0
brexanolone
0
Pregnanolone
BXO86P3XXW
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
727-735Références
J Clin Psychiatry. 2016 Sep;77(9):1189-1200
pubmed: 27780317
BMJ. 1997 Mar 29;314(7085):932-6
pubmed: 9099116
Br J Psychiatry. 1990 Aug;157:288-90
pubmed: 2224383
J Clin Psychiatry. 2015 May;76(5):562-9
pubmed: 25375652
Psychopharmacology (Berl). 2014 Mar;231(5):939-48
pubmed: 24173623
Front Psychol. 2016 Jun 24;7:938
pubmed: 27445906
Am J Psychiatry. 2004 Dec;161(12):2163-77
pubmed: 15569884
Natl Vital Stat Rep. 2019 Nov;68(13):1-47
pubmed: 32501202
Clin Obstet Gynecol. 2009 Sep;52(3):456-68
pubmed: 19661761
J Clin Psychiatry. 2013 Apr;74(4):393-9
pubmed: 23656847
Lancet. 2017 Jul 29;390(10093):480-489
pubmed: 28619476
Br J Psychiatry. 1989 Jun;154:813-7
pubmed: 2597888
Psychiatry Res. 2011 May 15;187(1-2):130-4
pubmed: 21122923
Nat Rev Dis Primers. 2018 Apr 26;4:18022
pubmed: 29695824
Expert Opin Pharmacother. 2014 Jun;15(9):1223-34
pubmed: 24773410
JAMA. 2016 Jan 26;315(4):388-406
pubmed: 26813212
Am J Psychiatry. 2012 Dec;169(12):1267-74
pubmed: 23212058
Arch Womens Ment Health. 2012 Oct;15(5):367-74
pubmed: 22983357
Obstet Gynecol. 2004 Apr;103(4):698-709
pubmed: 15051562
Lancet. 2018 Sep 22;392(10152):1058-1070
pubmed: 30177236
Perm J. 2005 Spring;9(2):70-3
pubmed: 21660168
Am J Obstet Gynecol. 2010 Apr;202(4):353.e1-6
pubmed: 20350642
MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):153-158
pubmed: 28207685
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Int Clin Psychopharmacol. 2002 Nov;17(6):281-5
pubmed: 12409681
Curr Med Res Opin. 2019 Mar;35(3):383-393
pubmed: 30468090
Front Psychiatry. 2018 Feb 01;8:248
pubmed: 29449816
Harv Rev Psychiatry. 2016 May-Jun;24(3):173-87
pubmed: 27148910
Obstet Gynecol. 2018 Nov;132(5):1314-1316
pubmed: 30629563
Br J Psychiatry. 1987 Jun;150:782-6
pubmed: 3651732
J Psychiatr Res. 2011 Feb;45(2):213-9
pubmed: 20542520
Prev Chronic Dis. 2014 Jun 19;11:E104
pubmed: 24945238
Obstet Gynecol. 2013 Nov;122(5):1122-1131
pubmed: 24150027
Health Technol Assess. 2010 Sep;14(43):iii-iv, ix-xi, 1-153
pubmed: 20860888
J Affect Disord. 2014 Jun;162:1-7
pubmed: 24766996
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Ann Fam Med. 2009 Jan-Feb;7(1):63-70
pubmed: 19139451
Int J Neuropsychopharmacol. 2005 Sep;8(3):445-9
pubmed: 15817137